Patents by Inventor Robert Kiss
Robert Kiss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Dynamic service discovery and offloading framework for edge computing based cellular network systems
Patent number: 11991260Abstract: A user equipment (UE) or other device performs service discovery of edge computing resources in a cellular network system and dynamic offloading of UE application tasks to discovered edge computing resources. As part of the discovery process, the device (e.g., the UE) may request edge server site capability information. When performing dynamic offloading, the UE may obtain (collect and/or receive) information regarding channel conditions, cellular network parameters or application requirements and dynamically determine whether a task of the application executing on the UE should be offloaded to an edge server or executed locally on the UE. In making decisions between offloaded or local execution, the UE may use a utility function that takes into account factors such as relative differences in application latency, energy consumption and offloading cost.Type: GrantFiled: December 17, 2020Date of Patent: May 21, 2024Assignee: Apple Inc.Inventors: Biljana Badic, Christian Drewes, Ralph Hasholzner, Krisztian Kiss, Teck Yang Lee, Matthias Sauer, Mikhail Vilgelm, Babar Qaisrani, Vijay Venkataraman, Robert Zaus -
Patent number: 11930442Abstract: Apparatuses, systems, and methods for reducing wireless device service interruptions. An indication of a disaster condition may be provided to a wireless device. The disaster condition may affect a home public land mobile network of the wireless device. The wireless device may perform cell selection in a manner influenced by the indication of the disaster condition. This may include considering cells associated with a forbidden public land mobile network for the cell selection, or excluding cells associated with the home public land mobile network of the wireless device that are unavailable, for example due to the disaster condition, among various possibilities.Type: GrantFiled: December 30, 2021Date of Patent: March 12, 2024Assignee: Apple Inc.Inventors: Sudeep Manithara Vamanan, Roland Gruber, Nirlesh Koshta, Anikethan Ramakrishna Vijaya Kumar, Sridhar Prakasam, Mona Agnel, Krisztian Kiss, Vijay Venkataraman, Haijing Hu, Robert Zaus
-
Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents
Patent number: 9181265Abstract: Novel phenazine derivatives of formula (I) are disclosed. In particular, substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines are disclosed. The compounds can be used as anti-angiogenic and/or anti-tumor agents.Type: GrantFiled: December 22, 2011Date of Patent: November 10, 2015Assignees: UNIVERSITE CATHOLIQUE DE LOUVAIN, UNIVERSITE LIBRE DE BRUXELLESInventors: Olivier Feron, Olivier Riant, Robert Kiss, Joelle Leclercq, Gabrielle Chataigne, Nicolas Vandelaer, Carole Lamy -
Patent number: 9168247Abstract: The invention provides novel beta-carboline derivatives of formulae (Ia) and (Ib) useful in the treatment of proliferative disorders including cancer, intermediates used in their preparation, processes for preparing the same and uses thereof.Type: GrantFiled: June 24, 2011Date of Patent: October 27, 2015Assignees: FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX, UNIVERSITE LIBRE BRUXELLESInventors: Raphael Frederick, Bernard Masereel, Jeremy Reniers, Johan Wouters, Celine Bruyere, Robert Kiss, Céline Anne Marie Michelle Meinguet, Véronique Emmanuelle Julie Mathieu
-
Patent number: 8772265Abstract: The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumor and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases.Type: GrantFiled: May 26, 2009Date of Patent: July 8, 2014Assignees: Universite Libre de Bruxelles, Universite de LiegeInventors: Philippe Neven, Didier Serteyn, Robert Kiss, Veronique Mathieu, Didier Cataldo, Natacha Rocks, Eva Scheer
-
Publication number: 20140005220Abstract: The invention provides novel beta-carboline derivatives of formulae (Ia) and (Ib) useful in the treatment of proliferative disorders including cancer, intermediates used in their preparation, processes for preparing the same and uses thereof.Type: ApplicationFiled: June 24, 2011Publication date: January 2, 2014Applicants: UNIVERSITE LIBRE DE BRUXELLES, FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIXInventors: Raphael Frederick, Bernard Masereel, Jeremy Reniers, Johan Wouters, Celine Bruyere, Robert Kiss
-
Publication number: 20130289030Abstract: The present invention is directed to novel compounds of formula I and their use as anti-angiogenic agents and anti-cancer agents.Type: ApplicationFiled: December 22, 2011Publication date: October 31, 2013Applicants: UNIVERSITE LIBRE DE BRUXELLES, UNIVERSITE CATHOLIQUE DE LOUVAINInventors: Olivier Feron, Olivier Riant, Robert Kiss, Joelle Leclercq, Gabrielle Chataigne, Nicolas Vandelaer, Carole Lamy
-
Publication number: 20130116273Abstract: The invention provides novel beta-carboline derivatives of formulae (Ia) and (Ib) useful in the treatment of proliferative disorders including cancer, intermediates used in their preparation, processes for preparing the same and uses thereof.Type: ApplicationFiled: June 24, 2011Publication date: May 9, 2013Applicants: UNIVERSITE LIBRE DE BRUXELLES, FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIXInventors: Raphael Frederick, Bernard Masereel, Jeremy Reniers, Johan Wouters, Celine Bruyere, Robert Kiss
-
Publication number: 20130053347Abstract: The present invention relates to the biology and mechanism of action of the naturally occurring compound Narciclasine, especially as an anti-cancer agent for brain tumors. The invention provides new insights on the target molecule of Amaryllidaceae isocarbostyril derivatives as for example Narciclasine and provides new prodrugs of these Amaryllidceae isocabostyril constituents for treating cancer, specifically cancers or tumors located in the brain.Type: ApplicationFiled: May 3, 2010Publication date: February 28, 2013Applicant: Universite Libre de BruxellesInventors: Veronique Mathieu, Gwendoline Van Goietsenoven, Jacques Dubois, Florence Lefranc-Kiss, Laurent Ingrassia, Robert Kiss
-
Publication number: 20110280940Abstract: The invention relates to the medical field, more precisely in the field of anti-cancer treatment and treatment of Alzheimer's disease, Parkinson's disease or Pick's disease or for ameliorating symptoms of Down syndrome, providing newly synthesised multi-vanilloyl derivative compounds and their use in the treatment of said disorders.Type: ApplicationFiled: October 13, 2009Publication date: November 17, 2011Inventors: Robert Kiss, Jacques Dubois, Jean Neve, Delphine Lamoral-Theys, Francois Dufrasne, Laurent Pottier
-
Publication number: 20110257126Abstract: The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumour and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases.Type: ApplicationFiled: May 26, 2009Publication date: October 20, 2011Applicants: Universite de Liege, Universite Libre de BruxellesInventors: Philippe Neven, Didier Serteyn, Jacques Delarge, Eva Scheer, Robert Kiss, Veronique Mathieu, Didier Cataldo, Natacha Rocks
-
Patent number: 7981875Abstract: Compounds and pharmaceutical compositions which include 2? oxo-voruscharin and derivatives are disclosed. The compounds and pharmaceutical compositions are useful in methods of treating cancer, particularly pancreatic cancer.Type: GrantFiled: December 13, 2007Date of Patent: July 19, 2011Assignees: Unibioscreen S.A., Universite Libre de BruxellesInventors: Eric Van Quaquebeke, Jean-Claude Braekman, Gentiane Simon, Pierre Guissou, Odile Germaine Nacoulma, Janique Dewelle, Francis Darro, Robert Kiss
-
Patent number: 7964575Abstract: The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of a medicament for treating and/or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma.Type: GrantFiled: March 9, 2006Date of Patent: June 21, 2011Assignees: Universite Libre de Bruxelles, Universite Catholique de LouvainInventors: Isabelle Camby, Patrick Henriet, Florence Lefranc, Pierre Courtoy, Robert Kiss
-
Patent number: 7741337Abstract: The present invention is directed to azonafide derivatives obtained by reacting azonafide with aldehydes, acyl halides, thioacyl halides, monoisocyanates, isothiocyanates, sulfonyl halides, monohalogenoalkanes, monohalogenoalkenes or monohalogenoalkynes, and are useful as active ingredients of pharmaceutical compositions for the prevention and treatment of cell proliferative disorders, in particular several forms of cancer.Type: GrantFiled: November 9, 2006Date of Patent: June 22, 2010Assignee: Unibioscreen S.A.Inventors: Eric Van Quaquebeke, Jérôme Tuti, Laurent Van den Hove, Robert Kiss, Francis Darro
-
Publication number: 20100120891Abstract: The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of a medicament for treating and/or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma.Type: ApplicationFiled: March 9, 2006Publication date: May 13, 2010Applicants: UNIVERSITE LIBRE DE BRUXELLES, UNIVERSITE CATHOLIQUE DE LOUVAINInventors: Isabelle Camby, Patrick Henriet, Florence Lefranc, Pierre Courtoy, Robert Kiss
-
Publication number: 20100076005Abstract: Isocarbostyril alkaloid derivatives having an anti-proliferative and anti-migratory activities are disclosed. In particular, compounds of formula (I) or (II), as well as stereoisomers, tautomers, racemates, prodrugs, metabolites thereof, pharmaceutically acceptable salt and/or solvate are encompassed which are useful in the treatment and prophylaxis of cancer. Methods of preparation are also disclosed.Type: ApplicationFiled: October 12, 2007Publication date: March 25, 2010Applicant: Unibioscreen SAInventors: Laurent Ingrassia, Lise Wlodarczak, Stephanie Thomas, Eric Van Quaquebeke, Laurent Van den Hove, Robert Kiss, Francis Darro
-
TARGETING OF ALPHA-1 OR ALPHA-3 SUBUNIT OF NA+, K+-ATPASE IN THE TREATMENT OF PROLIFERATIVE DISEASES
Publication number: 20100068198Abstract: Targeting of select subunits of the Na+,K+-ATPase is described, and especially the alpha-1 subunit and/or the alpha-3 subunit. Antisense agents, agents capable of causing RNA interference that can reduce the expression of Na+,K+-ATPase, and antibodies and antibody fragments and derivatives specific for Na+,K+-ATPase are useful as reagents and pharmaceutical formulations for the treatment of proliferative diseases, such as tumours and cancers. Methods and kits are also described.Type: ApplicationFiled: November 9, 2006Publication date: March 18, 2010Applicant: Unibioscreen S.A.Inventors: Tatjana Mijatovic, Eric Van Quaquebeke, Nancy Denève, Laurent Van den Hove, Francis Darro, Robert Kiss -
Publication number: 20090232907Abstract: Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods of treating specific types of cancer such as prostate, esophageal, glioblastoma, gliosarcoma, NSCLC, head and neck, and breast with the compounds described herein alone and in combination with antineoplastic agents.Type: ApplicationFiled: November 17, 2008Publication date: September 17, 2009Applicant: Unibioscreen S.A.Inventors: Eric Van Quaquebeke, Gentiane Simon, Mohamed El Yazidi, Jerome Tuti, Laurent Van Den Hove, Francis Darro, Robert Kiss
-
Publication number: 20090221628Abstract: Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods of treating specific types of cancer such as prostate, esophageal, glioblastoma, gliosarcoma, NSCLC, head and neck, and breast with the compounds described herein alone and in combination with antineoplastic agents.Type: ApplicationFiled: November 17, 2008Publication date: September 3, 2009Applicant: Unibioscreen S.A.Inventors: Eric Van Quaquebeke, Gentiane Simon, Mohamed El Yazidi, Jerome Tuti, Laurent Van Den Hove, Francis Darro, Robert Kiss
-
Compositions and methods for treatment of glioblastoma, gliosarcoma, NSCLC, and head and neck cancer
Publication number: 20090186915Abstract: Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods of treating specific types of cancer such as prostate, esophageal, glioblastoma, gliosarcoma, NSCLC, head and neck, and breast with the compounds described herein alone and in combination with antineoplastic agents.Type: ApplicationFiled: November 17, 2008Publication date: July 23, 2009Applicant: Unibioscreen S. A.Inventors: Eric Van Quaquebeke, Gentiane Simon, Mohamed El Yazidi, Jerome Tuti, Laurent Van Den Hove, Francis Darro, Robert Kiss